Literature DB >> 12832209

Characterization of self-assembled virus-like particles of human polyomavirus BK generated by recombinant baculoviruses.

Tian-Cheng Li1, Naokazu Takeda, Kenzo Kato, Josefina Nilsson, Li Xing, Lars Haag, R Holland Cheng, Tatsuo Miyamura.   

Abstract

The major structural protein of the human polyomavirus BK (BKV), VP1, was expressed by using recombinant baculoviruses. A large amount of protein with a molecular mass of about 42 kDa was synthesized and identified by Western blotting. The protein was detected exclusively in the nuclei by immunofluorescent analysis and it was released into culture medium. The expressed BKV VP1 protein was self-assembled into virus-like particles (BK-VLPs) with two different sizes (50 and 26 nm in diameter), which migrated into four different bands in CsCl gradient with buoyant densities of 1.29, 1.30, 1.33, and 1.35 g/cm(3). The immunological studies on the BK-VLPs suggested that they have similar antigenicity with those of authentic BKV particles. Cryoelectron microscopy and 3D image analysis further revealed that the larger BK-VLPs were composed of 72 capsomers which all were pentamers arranged in a T = 7 surface lattice. This system provides useful information for detailed studies of viral morphogenesis and the structural basis for the antigenicity of BKV.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12832209     DOI: 10.1016/s0042-6822(03)00141-7

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  20 in total

Review 1.  BK polyomavirus: emerging pathogen.

Authors:  Shauna M Bennett; Nicole M Broekema; Michael J Imperiale
Journal:  Microbes Infect       Date:  2012-02-24       Impact factor: 2.700

2.  Latent infection of a new alphanodavirus in an insect cell line.

Authors:  Tian-Cheng Li; Paul D Scotti; Tatsuo Miyamura; Naokazu Takeda
Journal:  J Virol       Date:  2007-08-08       Impact factor: 5.103

Review 3.  BK Polyomavirus: Clinical Aspects, Immune Regulation, and Emerging Therapies.

Authors:  George R Ambalathingal; Ross S Francis; Mark J Smyth; Corey Smith; Rajiv Khanna
Journal:  Clin Microbiol Rev       Date:  2017-04       Impact factor: 26.132

4.  Role of cell-type-specific endoplasmic reticulum-associated degradation in polyomavirus trafficking.

Authors:  Shauna M Bennett; Mengxi Jiang; Michael J Imperiale
Journal:  J Virol       Date:  2013-06-05       Impact factor: 5.103

5.  Structure and assembly of a T=1 virus-like particle in BK polyomavirus.

Authors:  Josefina Nilsson; Naoyuki Miyazaki; Li Xing; Bomu Wu; Lena Hammar; Tian Cheng Li; Naokazu Takeda; Tatsuo Miyamura; R Holland Cheng
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

6.  Minor capsid proteins of simian virus 40 are dispensable for nucleocapsid assembly and cell entry but are required for nuclear entry of the viral genome.

Authors:  Akira Nakanishi; Noriko Itoh; Peggy P Li; Hiroshi Handa; Robert C Liddington; Harumi Kasamatsu
Journal:  J Virol       Date:  2007-01-31       Impact factor: 5.103

7.  Early events during BK virus entry and disassembly.

Authors:  Mengxi Jiang; Johanna R Abend; Billy Tsai; Michael J Imperiale
Journal:  J Virol       Date:  2008-11-26       Impact factor: 5.103

8.  Antibody responses to recombinant polyomavirus BK large T and VP1 proteins in young kidney transplant patients.

Authors:  Sohrab Bodaghi; Patrizia Comoli; Robert Bösch; Alberta Azzi; Rainer Gosert; David Leuenberger; Fabrizio Ginevri; Hans H Hirsch
Journal:  J Clin Microbiol       Date:  2009-05-27       Impact factor: 5.948

Review 9.  BK virus and human cancer: innocent until proven guilty.

Authors:  Johanna R Abend; Mengxi Jiang; Michael J Imperiale
Journal:  Semin Cancer Biol       Date:  2009-02-21       Impact factor: 15.707

10.  Adenovirus dodecahedron, as a drug delivery vector.

Authors:  Monika Zochowska; Agnieszka Paca; Guy Schoehn; Jean-Pierre Andrieu; Jadwiga Chroboczek; Bernard Dublet; Ewa Szolajska
Journal:  PLoS One       Date:  2009-05-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.